Amylin Pharmaceuticals

M&A in the biotech and pharmaceutical industries continues. Bristol-Myers Squibb (NYSE: BMY) just announced it has agreed to acquire Amylin Pharmaceuticals (NASDAQ: AMLN) for $5.3 billion. And Human Genome Sciences (NASDAQ: HGSI) has opened itself up to bidders, including GlaxoSmithKline (NYSE...

Jefferies is out with its report today on Amylin Pharmaceuticals (NASDAQ: AMLN), maintaining Buy. In a note to clients, Jefferies writes, "Today, AMLN reported that the Bydureon thorough QT (tQT) study did not show prolongation of the QT interval. We believe this positive outcome, which is in line...

Citi provided color on Amylin Pharmaceuticals (NASDAQ: AMLN). In a research report published today, Citi commented on the company's new drug Bydureon. In the report, Citi states, “Amylin presented a poster at the ADA meeting showing the QTcF (heart conduction) data on Bydureon… The data showed...

Collins Stewart reiterated its Sell rating and PT of $9 on Amylin Pharmaceuticals (NASDAQ: AMLN). On Friday, Amylin finished the day at $11.83.

Piper Jaffray is out with its report today on Amylin Pharmaceuticals (NASDAQ: AMLN), maintaining Overweight after ECG data was just released from the DURATION 1 Phase III trial of Bydureon. In a note to clients, Piper Jaffray writes, "We believe this ECG data could mitigate concerns related to...

Jefferies is out with its report today on Amylin Pharmaceuticals (NASDAQ: AMLN), maintaining Buy. In a note to clients, Jefferies writes, "We viewed AMLN's presentations on QT data from DURATION-1 and new data on Byetta once monthly as incremental positives for the stock. We also see the...

J.P. Morgan is recapping script data from Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN). “In this note, we recap key script data in the diabetes drug landscape with a focus on the GLP-1 market,” J.P. Morgan writes. “Specifically for the week ended June 3, Byetta TRx was low and NRx was in line with...

According to Morgan Stanley, Amylin Pharmaceuticals (NASDAQ: AMLN) risks remain. Morgan Stanley said that it believes the latest update on the ongoing Amylin/Lilly legal battle accentuates the risks to Amylin. “While this decision is not on the breach of contract, we see most outcomes of that...

Citi is commenting on drug results from Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN). “GLP-1 TRx and NRx scrips (Byetta + Victoza) are up 1.6% and down 0.3% wk/wk, respectively,” Citi writes. “Overall the GLP-1 market has grown nicely since Victoza's launch as indicated by the 4 wk average (TRx +34...

According to Deutsche Bank, it will be holding its 36th Annual Healthcare Conference in Boston on May 2nd-4th. Top companies in the healthcare industry will be in attendance, Deutsche Bank explains, “The conference will feature senior managements from many of the leading healthcare companies as...

Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) presented a positive QTc analysis (QTcI) of Byetta data the Street has been awaiting, “which implies less concerning QTc increases with higher exenatide doses,” Jefferies reports. “We remain positive on upcoming Bydureon QTc data and prospects for...

Hapoalim Securities is downgrading shares of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) to Hold from Buy.

Piper Jaffray is upgrading Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) to Overweight from Neutral and raising its price-target to $20 from $14 following an agreement reached with the FDA for a study design that reduces tQT trial risk.

Jefferies & Company said that it continues to believe that there is upside to Amylin Pharmaceuticals, Inc.'s (NASDAQ: AMLN) YE2011 guidance for Bydureon resubmission and remain positive on the Bydureon commercial opportunity. Amylin Pharmaceuticals closed Friday at $13.79.